Follow FrankTwisk on Twitter  
   

 

 

 

 

Ruscetti/Mikovits:

bij meer dan 75%

van de ME/CVS-patiŽnten

XMRV gekonstateerd

(presentatie ICMAOI, 2010)

 

 

 

 


 

 

Dr. Francis Ruscetti (van het Amerikaanse Kankerinstituut NCI) presenteerde in april op een internationaal kongres de resultaten van recent onderzoek naar XMRV bij ME/CVS-patienten.

 

Bij meer dan drie-kwart van de patiŽnten werd m.b.v. ťťn of meer technieken XMRV vastgesteld.

 

 


 

Repeated Detection of Infectious Xenotropic Murine Virus-Related Virus (XMRV)

in Human Neoplasia and Neuroimmune Diseases

12th Intl. Conf. on Malignancies in AIDS and Other Acquired Immunodeficiences, Apr 26, 2010.

Francis Ruscetti, Vincent Lombardi, Max Pfost, Kathryn Hagen, Judy Mikovits.

 

http://www.prohealth.com/library/showarticle.cfm?libid=15496

 

 

(Note: This abstract, of a presentation given April 26 by National Cancer Institute researcher Frank Ruscetti, is listed in the conference agenda & program book as "Pathogenic Consequences of Xenotropic Murine Virus-Related Virus (XMRV) Expression in the Development of Chronic Diseases. "Neoplasia" refers to abnormal tissue proliferation, as in a tumor.)

 

 

Background:

 

In 2006,

sequences of

a novel human retrovirus, XMRV,

were identified and

reported to be

associated with

a subset of

hereditary prostate cancer.

 

Although the public health implications

of this finding

were not immediately clear,

two recent papers show

XMRV is clearly a health concern.

  • One clearly shows that XMRV expression in the proliferating prostate stroma and epithelium of prostate cancer patients [1].
  • The second describes the detection of XMRV in about two-thirds of patients diagnosed with chronic fatigue syndrome [2].

We will present

data that

in these and

other neuroimmune diseases

and cancers,

the host mounts

a humoral response

[involving antibodies]

to XMRV and

infected patients

are viremic

[virus particles in the bloodstream].

 

 

Methods:

 

A combination of

classical retroviral methods,

including RT-PCR,

full-length genomic sequencing,

immunoblotting

of viral expression

in activated PBMC,

passage of infectious virus

in plasma and

PBMC

to indicator cell lines, and

presence of antibodies to XMRV

in plasma,

allowed XMRV detection

in more than 75% of

the CFS patients studied

 

Since then,

several publications in Europe

using DNA-PCR of

blood products

failed to detect

XMRV sequences in

patients with either disease and

have created considerable controversy.

 

Reliable methods

for

the biological and

molecular amplification

to detect XMRV

in

unstimulated blood cells and

plasma

have been developed.

 

Some DNA-PCR negative patient blood samples

represent false negatives, and

molecular analysis

using DNA

from unstimulated blood cells

is not yet sufficient

for XMRV identification.

 

 

Results:

 

In mice,

viruses

related to XMRV

cause B-cell lymphoma

usually by

insertional mutagenesis

activating

a cellular oncogene

as well as

causing chronic neurological diseases.

 

We will present

a case of

development of

such B cell lymphoma

in CFS patients.

XMRV-infected

individuals with

both neuroimmune disease and

cancer

develop an immune response to XMRV.

 

The isolation of

infectious XMRV

from prostate cancer patients

will be shown for the first time.

 

Pathogenic consequences of

this infection

will be discussed

 

 

Conclusion:

 

XMRV,

a retrovirus of

unknown pathogenic potential,

is infectious in humans.

 

 

References:

  1. Schlaberg et al.: "XMRV is present in malignant prostate epithelium and is associated with prostate cancer." Proc Natl Acad Sci U S A 106:16351, 2009.
  2. Lombardi et al.: "Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome." Science 326:585, 2009.

 

 

http://oham.cancer.gov/objects/pdf/2010ICMAOI_Program_Book.pdf

bladzijde 23

 

 


 

Met dank aan Erik.